Approaches to Managing Benzodiazepines (March 2020 PT)

Activity Preview

Benzodiazepines are first-line treatments for acute alcohol withdrawal and may be used as acute anticonvulsants. Long-term use of benzodiazepines has been known to produce complications related to discontinuation, withdrawal symptoms, increased risk of accidental overdose when combined with other central nervous system depressants, persistence of benzodiazepine-related adverse effects, physical dependence, and benzodiazepines use disorders. This activity will discuss patients at risk for complications and discuss appropriate strategies to tapering benzodiazepines.

Learning Objectives

At the completion of this activity, the participant will be able to:

  1. Identify patients at risk for complications and adverse events related to use of a benzodiazepine.
  2. Discuss appropriate strategies to tapering benzodiazepines.
  3. Recognize benzodiazepine withdrawal symptoms and other potential complications related to tapering.
  4. Describe appropriate uses of a benzodiazepine.

Activity type: Knowledge-based

Target Audience: Pharmacists 

Learning level: 2

Accreditation Information

The American Pharmacists Association is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.  This activity is approved for 2.0 contact hours of CPE credit (0.20 CEUs). The ACPE Universal Activity Number for this activity is 0202-0000-19-298-H01-P.  

To obtain credit for Approaches to Managing Benzodiazepines, complete the assessment with a grade of 70% or better, complete the evaluation, and then claim credit. Participants need to have a valid pharmacist.com username and password to claim credit. After credit has been claimed, please visit CPE monitor for your transcript.

APhA's continuing pharmacy education policy allows two opportunities to successfully complete the continuing pharmacy education assessment. Please note that the questions may not appear in the same order as printed and only two attempts to pass the assessment will be granted.  The current policy of the APhA Education Department is to not release the correct answers to any of our CPE tests. This policy is intended to maintain the integrity of the CPE activity and the assessment.

Initial release date: March 1, 2020
Expiration date: December 20, 2022

Development

Approaches to Managing Benzodiazepines is a home-study continuing education activity for pharmacists developed by the American Pharmacists Association.

Advisory Board

Jeffrey Gold, PharmD, BCPP, Mental Health Psychiatric Pharmacy Specialist, Rocky Mountain Regional VA Medical Center, Aurora, CO

Helen Sairany, PharmD, MBA, BCACP, Director of Content Development and Partnership, APhA 

Disclosures

Jeffrey Gold, PharmD, BCPP; Helen Sairany, PharmD, MBA, BCACP; and APhA’s editorial staff declare no conflicts of interest or financial interests in any product or service mentioned in this activity, including grants, employment, gifts, stock holdings, and honoraria. For complete staff disclosures, please see the Education and Accreditation Information section at www.pharmacist.com/apha-disclosures.

Fee

There is no fee associated with this activity for members of the American Pharmacists Association. There is a $25 fee for nonmembers.

System Requirements

Computer and internet access are required to complete this activity.  To view the Technology System Requirements, please visit our website.